Journal
ONCOTARGETS AND THERAPY
Volume 11, Issue -, Pages 4137-4147Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S172305
Keywords
VEGF; VEGFR-2; apatinib; angiogenesis; solid tumors; gastric cancer
Categories
Funding
- Taishan Scholar foundation [tshw201502061]
- Qingdao People's Livelihood Science and Technology Program [16-6-2-3-nsh]
- Qingdao Entrepreneurial Innovation Leading Talent Program
Ask authors/readers for more resources
With the investigation of molecular targets, many agents, such as trastuzumab and ramucirumab, have attained a positive outcome in oncotherapy. Vascular endothelial growth factor (VEGF) is considered a potent factor in angiogenesis and plays an important role in the growth of tumors. Moreover, both VEGF and its receptor are usually excessively expressed in solid tumors and could be hopeful targets for the treatment of neoplasms. Apatinib (YN968D1) is an oral small-molecule tyrosine kinase inhibitor of VEGFR-2. By inhibiting several signaling transduction pathways, it restrains angiogenesis and subsequently controls tumorigenesis. According to current studies, apatinib shows promising application in various solid tumors as a post-second-and post-third-line treatment. It could significantly improve the median overall survival and progression-free survival of patients with tolerated adverse reactions. This paper aims to summarize the recent research on apatinib including the mechanism, pharmacokinetics, trials, adverse reactions, and prospect as a treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available